April 16, 2018 10:56 AM EDTUpdated 11:09 AM
News Briefing

Genen­tech inks $359M deal with Kine­ta; Celldex bat­tered af­ter ADC flops in PhI­Ib

Amber Tong

→ Genen­tech is com­mit­ting up to $359 mil­lion to pur­sue a nov­el tar­get for chron­ic neu­ro­path­ic pain. Their part­ner in this ex­clu­sive op­tion and …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

Am­gen’s once-a-month obe­si­ty shot shows 20% weight loss af­ter a year

Roche buys out CAR-T part­ner Po­sei­da for $1B up­front

Alec­tor says Alzheimer's pro­gram tar­get­ing mi­croglia fails Phase 2, stock dives

How did Trump’s FDA pick land? Biotech stocks are up, and ex­ec­u­tives are (most­ly) re­lieved

Trump team asked Warp Speed leader to head NIH, may seek more tra­di­tion­al pick for role

Roche’s TIG­IT drug miss­es last shot at sur­vival end­point win in Phase 3 lung can­cer tri­al

A service from the Financial Times